Cite
Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine.
MLA
Pusic, Kae, et al. “Iron Oxide Nanoparticles as a Clinically Acceptable Delivery Platform for a Recombinant Blood-Stage Human Malaria Vaccine.” FASEB Journal, vol. 27, no. 3, Mar. 2013, pp. 1153–66. EBSCOhost, https://doi.org/10.1096/fj.12-218362.
APA
Pusic, K., Aguilar, Z., McLoughlin, J., Kobuch, S., Hong Xu, Tsang, M., Wang, A., & Hui, G. (2013). Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine. FASEB Journal, 27(3), 1153–1166. https://doi.org/10.1096/fj.12-218362
Chicago
Pusic, Kae, Zoraida Aguilar, Jaclyn McLoughlin, Sophie Kobuch, Hong Xu, Mazie Tsang, Andrew Wang, and George Hui. 2013. “Iron Oxide Nanoparticles as a Clinically Acceptable Delivery Platform for a Recombinant Blood-Stage Human Malaria Vaccine.” FASEB Journal 27 (3): 1153–66. doi:10.1096/fj.12-218362.